Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.

Future oncology (London, England) - 1 Sept 2022

Lampaki Sofia, Mountzios Giannis, Georgoulias Vassilis, Rapti Aggeliki, Xanthakis Ioannis, Baka Sofia, Mavroudis Dimitrios, Samantas Epaminondas, Athanasiadis Elias, Zagouri Flora, Charpidou Andriani, Somarakis Alvertos, Papista Christina, Nikolaou Aristeidis, Anastasopoulou Eleftheria, Paparepa Zoe, Syrigos Konstantinos N

Abstract excerpt

Aim: To retrospectively characterize real-world therapeutic strategies, clinical outcomes and attrition rates with EGFR tyrosine kinase inhibitors (TKIs), before first-line osimertinib approval, in EGFR-mutated advanced/metastatic non-small-cell lung cancer patients in Greece. Results: Among 160 patients, the discontinuation rate for first-line first- or second-generation EGFR-TKIs was 85%; among these patients,...

Topics

Join the communities discussing this publication.

Acrylamides
Aniline Compounds
Carcinoma, Non-Small-Cell Lung
ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Source

Identifiers

PMID: 35929414
DOI: 10.2217/fon-2022-0386

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.PMID 35929414Read ↗

Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.Semantic proximity Read ↗

Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.Semantic proximity Read ↗

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study.Semantic proximity Read ↗

A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study.Semantic proximity Read ↗

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First or Second Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer: The ‘LUNGFUL’ StudySemantic proximity Read ↗

Osimertinib in Advanced EGFR-T790M Mutation-positive Non-small Cell Lung Cancer Patients Treated Within the Special Use Medication Program in Spain. OSIREX-spanish Lung Cancer GroupSemantic proximity Read ↗

A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.Semantic proximity Read ↗

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer.Semantic proximity Read ↗

Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients.Semantic proximity Read ↗

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.Semantic proximity Read ↗

Empirical Osimertinib as a Second-Line Treatment Is a Viable Option Following First- and Second-Generation TKI Therapy With Unknown EGFR Status in Treated Non-Small Cell Lung Cancer: A Retrospective Study.Semantic proximity Read ↗

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.